MedTrace Logo

Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy

NCT03027245 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 353

Last updated 2022-07-13

No results posted yet for this study

Summary

Study E7389-M044-504 is an observational, post-authorization, single-arm, prospective, multicenter cohort study conducted to characterize and determine the incidence of eribulin-induced peripheral neuropathy (PN), and the frequency and time to resolution of eribulin-induced PN in adult participants treated with eribulin in a real-life setting with locally advanced or metastatic breast cancer (MBC) who have progressed following at least one and up to three chemotherapeutic regimens for advanced disease.

Conditions

Interventions

DRUG

Eribulin

Sponsors & Collaborators

  • Eisai GmbH

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-13
Primary Completion
2022-05-31
Completion
2022-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03027245 on ClinicalTrials.gov